[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT04686305":3,"trial-entities:NCT04686305":715,"trial-summary:NCT04686305":719},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":17,"conditions":18,"keywords":20,"study_type":36,"primary_purpose":37,"phases":38,"enrollment_info":40,"interventions":43,"primary_outcomes":88,"secondary_outcomes":93,"sex":126,"minimum_age":127,"maximum_age":128,"healthy_volunteers":15,"eligibility_criteria":129,"std_ages":157,"locations":160,"central_contacts":695,"overall_officials":705,"references":706,"see_also_links":711},"NCT04686305","D967YC00001","Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC","A Phase Ib Multicenter, Open-label Study to Evaluate the Safety and Tolerability of Trastuzumab Deruxtecan (T-DXd) and Immunotherapy Agents With and Without Chemotherapy Agents in First-line Treatment of Patients With Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) and Human Epidermal Growth Factor Receptor 2 (HER2) Overexpression (OE) (DESTINY-Lung03)","RECRUITING","2027-06-30","2026-02","2026-04-13","2021-03-09","AstraZeneca","INDUSTRY",false,"DESTINY-Lung03 will investigate the safety and tolerability of trastuzumab deruxtecan in combination with Immunotherapy Agents with and without chemotherapy in patients with HER2 over-expressing non-small cell lung cancer. The efficacy will be also analyzed as a secondary endpoint.","Part 1 is a dose escalation study by design, allowing the assessment of safety, tolerability, and recommended dose levels of the combination of T-DXd and durvalumab plus cisplatin, carboplatin, or pemetrexed. No more patients will be enrolled in this part of the study. Part 2, expansions in the treatment-naïve setting on any recommended dose level, will not be initiated.\n\nThe evaluation of T-DXd combination treatment with immunotherapy continues in Part 3, Part 4, and Part 5. In Part 3, T-DXd is assessed in combination with volrustomig, with carboplatin (Arm 3B) or without carboplatin (Arm 3A). Part 4 examines T-DXd with rilvegostomig, either with carboplatin (Arm 4B) or without carboplatin (Arm 4A). In Part 5, T-DXd is evaluated with volrustomig, given with or without a priming dose followed by a fixed dose in Arm 5A. There is also an optional Arm 5B at the Sponsor's discretion. These parts focus on further dose optimization for first-line HER2-overexpressing NSCLC.\n\nFor Part 3, patients will be randomized to Arms 3A and 3B, beginning with the cohorts receiving the volrustomig starting dose (SD). A total of 6 DLT-evaluable patients will be enrolled to the SD cohorts in each arm. If the combination of T-DXd with volrustomig at the starting dose is deemed safe, a dose escalation (E1) cohort will be opened for 6 DLT-evaluable patients. Once all open dose confirmation cohorts have 6 DLT-evaluable patients, the SRC will convene to select the volrustomig RP2D to be used in the dose-expansion (DE) cohorts of each arm (n=34). Part 3 is now permanently closed to recruitment; no further patients will be enrolled.\n\nIn Part 4, once a total of 6 DLT-evaluable patients\u002Farm have been enrolled into Arm 4A and Arm 4B safety-run in (SR) cohorts and deemed safe, an additional 34 patients per arm will be enrolled in Arms 4A and 4B in dose expansion cohorts.\n\nPart 5 involves additional dosing regimens of T-DXd in combination with volrustomig. The objective of Part 5 is to evaluate the safety and efficacy of priming and flat dosing regimens in 2 different cohorts of up to 30 patients per arm.\n\nThe target population of interest (for Part 3, 4 and 5) are patients with advanced or metastatic non-small cell lung cancer measurable disease by RECIST 1.1 criteria, HER2 overexpression, ECOG PS of 0 to 1, patients who are treatment naïve for recurrent, unresectable or metastatic disease. Patients with tumors that harbor a known genomic alteration or driver for which approved therapies are available are excluded.",[19],"Locally Advanced or Metastatic Non-Small Cell Lung Cancer",[21,22,23,24,25,26,27,28,29,30,31,32,33,34,35],"HER2+","HER2 expression","DS-8201a","T-DXd","Trastuzumab Deruxtecan","Volrustomig (MEDI5752)","Antibody - drug conjugate","bispecific antibody","Volrustomig","Rilvegostomig","Carboplatin","First line","Locally advanced and unresectable non-squamous NSCLC","Metastatic non-squamous NSCLC","Non-small cell lung cancer","INTERVENTIONAL","TREATMENT",[39],"PHASE1",{"count":41,"type":42},304,"ESTIMATED",[44,60,67,71,74,78,83],{"type":45,"name":24,"description":46,"armGroupLabels":47,"otherNames":58},"DRUG","T-DXd: administered as an IV infusion",[48,49,50,51,52,53,54,55,56,57],"Arm 1A: T-DXd, Durvalumab and Cisplatin","Arm 1B: T-DXd, Durvalumab and Carboplatin","Arm 1C: T-DXd, Durvalumab and Pemetrexed","Arm 1D: T-DXd","Arm 3A: T-DXd and Volrustomig","Arm 3B: T-DXd, Volrustomig and Carboplatin","Arm 4A: T-DXd and Rilvegostomig","Arm 4B T-DXd and Rilvegostomig with Carboplatin","Arm 5A: T-DXd and Volrustomig","Arm 5B: T-DXd and Volrustomig",[59],"DS-8201a, Trastuzumab deruxtecan",{"type":61,"name":62,"description":63,"armGroupLabels":64,"otherNames":65},"BIOLOGICAL","Durvalumab","Durvalumab: administered as an IV infusion",[48,49,50],[66],"MEDI4736",{"type":45,"name":68,"description":69,"armGroupLabels":70},"Cisplatin","Cisplatin: administered as an IV infusion",[48],{"type":45,"name":31,"description":72,"armGroupLabels":73},"Carboplatin: administered as an IV infusion",[49,53,55],{"type":45,"name":75,"description":76,"armGroupLabels":77},"Pemetrexed","Pemetrexed: administered as an IV infusion (drug not used)",[50],{"type":45,"name":29,"description":79,"armGroupLabels":80,"otherNames":81},"Volrustomig: administered as an IV infusion",[52,53,56,57],[82],"Other Name: MEDI5752",{"type":45,"name":30,"description":84,"armGroupLabels":85,"otherNames":86},"Rilvegostomig: administered as an IV infusion",[54,55],[87],"Other Name: AZD2936",[89],{"measure":90,"description":91,"timeFrame":92},"Frequency of AEs and SAEs","Occurrence of AEs and SAEs graded according to NCI CTCAE v5.0","Safety and tolerability (and to determine RP2D) will be assessed for approximately 20 months from informed consent",[94,98,102,105,108,111,114,117,120,123],{"measure":95,"description":96,"timeFrame":97},"Confirmed Objective Response Rate (ORR)","Confirmed ORR per RECIST 1.1 is the percentage of patients with Complete Response or Partial Response that is subsequently confirmed, based on investigator assessment","An average of approximately 12 months",{"measure":99,"description":100,"timeFrame":101},"Duration of Response (DoR)","DOR is defined as the time from the date of first documented response until the date of documented progression or death, based on RECIST 1.1 assessment","An average of approximately 20 months",{"measure":103,"description":104,"timeFrame":97},"Disease Control Rate (DCR)","DCR is the percentage of patients who have a best overall response of complete response (CR) or partial response (PR) or stable disease (SD), based on RECIST 1.1 assessment. DCR is assessed at 6 and 12 weeks",{"measure":106,"description":107,"timeFrame":101},"Progression-free survival (PFS)","PFS is the time from first dose of study treatment until the date of objective disease progression or death, based on RECIST 1.1 assessment",{"measure":109,"description":110,"timeFrame":101},"Overall survival (OS)","OS is the time form the date of first dose of study treatment until death due to any cause",{"measure":112,"description":113,"timeFrame":101},"Pharmacokinetics (PK) assessed by the serum concentration of T-DXd, total anti-HER2 antibody, and MAAA-1181 in all arms","Individual patient data and descriptive statistics will be provided for serum concentration data at each time point for T-DXd, total anti-HER2 antibody and MAAA-1181a",{"measure":115,"description":116,"timeFrame":101},"Pharmacokinetics (PK) assessed by the serum concentration of durvalumab in study arms including T-DXd in combination with durvalumab","Individual patient data and descriptive statistics will be provided for serum concentration data at each time point for durvalumab, including T-DXd in combination with durvalumab",{"measure":118,"description":119,"timeFrame":101},"Pharmacokinetics (PK) assessed by the serum concentration of volrustomig in study arms including T-DXd in combination with volrustomig","Individual patient data and descriptive statistics will be provided for serum concentration data at each time point for volrustomig, including T-DXd in combination with volrustomig",{"measure":121,"description":122,"timeFrame":101},"Pharmacokinetics (PK) assessed by the serum concentration of rilvegostomig in study arms including T-DXd in combination with rilvegostomig","Individual patient data and descriptive statistics will be provided for serum concentration data at each time point for rilvegostomig, including T- DXd in combination with rilvegostomig",{"measure":124,"description":125,"timeFrame":101},"The immunogenicity of T-DXd, durvalumab, volrustomig and rilvegostomig assessed by the presence of ADAs for T-DXd, durvalumab, volrustomig, or rilvegostomig","Individual participant data and descriptive statistics will be provided for data at each time point for each dose level for T-DXd, durvalumab or volrustomig, or rilvegostomig","ALL","18 Years",null,{"inclusion":130,"exclusion":140,"raw_text":156},[131,132,133,134,135,136,137,138,139],"Histologically documented unresectable locally advanced\u002Fmetastatic non-squamous NSCLC","Part 1: Progression after 1 or 2 lines of systemic therapy for recurrent or metastatic setting.","Part 3, Part 4 and Part 5: Patients must have tumors that do not harbor known genomic alterations or actionable driver kinases, for which approved therapies are available are allowed.","Part 3, Part 4 and Part 5: Patient must be treatment-naïve for advanced or metastatic NSCLC. Patients who have received prior adjuvant, or neoadjuvant chemotherapy, or definitive chemoradiation for advanced disease are eligible, provided that progression has occurred \\> 6 months from end of last therapy","HER2overexpression status as determined by central review of tumor tissue","WHO \u002F ECOG performance status of 0 or 1","Measurable target disease assessed by the investigator using RECIST 1.1","Has protocol defined adequate organ and bone marrow function","Part 3, Part 4 and Part 5: Minimum body weight of 35 kg.",[141,142,143,144,145,146,147,148,149,150,151,152,153,154,155],"HER2 mutation if previously known","Has a history of (non-infectious) ILD\u002Fpneumonitis that required steroids, has current ILD\u002Fpneumonitis, or where suspected ILD\u002Fpneumonitis cannot be ruled out by imaging at screening","Lung-specific intercurrent clinically significant illnesses including, but not limited to, any underlying pulmonary disorder and prior pneumonectomy","Active primary immunodeficiency known HIV infection, or active chronic and resolved hepatitis B (positive hepatitis B virus surface antigen \\[HBsAg+ve\\] or hepatitis B virus core antibody (anti-HBc +ve) regardless of HBV DNA level)) or hepatitis C infection. Patients positive for HCV antibody are eligible only if polymerase chain reaction is negative for HCV RNA. Patients should be tested for HIV prior to treatment assignment if required by local regulations or IRB\u002FEC","Active infection including tuberculosis and uncontrolled infection requiring IV antibiotics, antivirals, or antifungals","Spinal cord compression or clinically active central nervous system metastases, defined as untreated and symptomatic, or requiring therapy with corticosteroids or anticonvulsants to control associated symptoms","Medical history of myocardial infarction within 6 months before treatment assignment, symptomatic CHF (New York Heart Association Class II to IV), clinically important cardiac arrhythmias, or a recent (\\\u003C 6 months) cardiovascular event including stroke","For Part 3, Part 4 and Part 5: Cardiomyopathy of any etiology, symptomatic CHF (as defined by New York Heart Association Class \\> II), unstable angina pectoris, history of MI within the past 12 months, or cardiac arrhythmia are to be excluded. Patients with troponin levels above ULN at screening (as defined by the manufacturer), and without any myocardial related symptoms, should have a cardiologic consultation before treatment assignment to rule out acute cardiopulmonary events.","Ascites or pericardial effusion that requires drainage, peritoneal shunt, Pleuroperitoneal shunt or CART (Concentrated Ascites Reinfusion Therapy)","For Part 3, Part 4 and Part 5: Active non-infectious skin disease (including any grade rash, urticarial, dermatitis, ulceration, or psoriasis) requiring systemic treatment, active or prior documented autoimmune or inflammatory disorders requiring chronic treatment with steroids or other immunosuppressive treatment.","Unresolved toxicities not yet resolved to Grade ≤ 1 or baseline from previous anticancer therapy OR prior discontinuation of any planned study therapy due to toxicity.","must not have any medical contraindication to platinum-based chemotherapy.","Part 3, Part 4 and Part 5 patients must not have had prior exposure to anti-PD-1, anti-PD-L1, anti-CTLA-4, anti-TIGIT or any other experimental immunotherapy in any setting.","For Part 3, Part 4 and Part 5: History of substance abuse or any other medical or psychological conditions that may, in the opinion of the Investigator, interfere with the subject's participation in the clinical study or evaluation of the clinical study results","For Part 3, Part 4 and Part 5: History of thromboembolic events within 3 months before the first dose of IP (limited to pulmonary embolism, deep vein thrombosis, or cerebral venous sinus thrombosis).","Inclusion criteria:\n\n* Histologically documented unresectable locally advanced\u002Fmetastatic non-squamous NSCLC\n* Part 1: Progression after 1 or 2 lines of systemic therapy for recurrent or metastatic setting.\n* Part 3, Part 4 and Part 5: Patients must have tumors that do not harbor known genomic alterations or actionable driver kinases, for which approved therapies are available are allowed.\n* Part 3, Part 4 and Part 5: Patient must be treatment-naïve for advanced or metastatic NSCLC. Patients who have received prior adjuvant, or neoadjuvant chemotherapy, or definitive chemoradiation for advanced disease are eligible, provided that progression has occurred \\> 6 months from end of last therapy\n* HER2overexpression status as determined by central review of tumor tissue\n* WHO \u002F ECOG performance status of 0 or 1\n* Measurable target disease assessed by the investigator using RECIST 1.1\n* Has protocol defined adequate organ and bone marrow function\n* Part 3, Part 4 and Part 5: Minimum body weight of 35 kg.\n\nExclusion criteria:\n\n* HER2 mutation if previously known\n* Has a history of (non-infectious) ILD\u002Fpneumonitis that required steroids, has current ILD\u002Fpneumonitis, or where suspected ILD\u002Fpneumonitis cannot be ruled out by imaging at screening\n* Lung-specific intercurrent clinically significant illnesses including, but not limited to, any underlying pulmonary disorder and prior pneumonectomy\n* Active primary immunodeficiency known HIV infection, or active chronic and resolved hepatitis B (positive hepatitis B virus surface antigen \\[HBsAg+ve\\] or hepatitis B virus core antibody (anti-HBc +ve) regardless of HBV DNA level)) or hepatitis C infection. Patients positive for HCV antibody are eligible only if polymerase chain reaction is negative for HCV RNA. Patients should be tested for HIV prior to treatment assignment if required by local regulations or IRB\u002FEC\n* Active infection including tuberculosis and uncontrolled infection requiring IV antibiotics, antivirals, or antifungals\n* Spinal cord compression or clinically active central nervous system metastases, defined as untreated and symptomatic, or requiring therapy with corticosteroids or anticonvulsants to control associated symptoms\n* Medical history of myocardial infarction within 6 months before treatment assignment, symptomatic CHF (New York Heart Association Class II to IV), clinically important cardiac arrhythmias, or a recent (\\\u003C 6 months) cardiovascular event including stroke\n* For Part 3, Part 4 and Part 5: Cardiomyopathy of any etiology, symptomatic CHF (as defined by New York Heart Association Class \\> II), unstable angina pectoris, history of MI within the past 12 months, or cardiac arrhythmia are to be excluded. Patients with troponin levels above ULN at screening (as defined by the manufacturer), and without any myocardial related symptoms, should have a cardiologic consultation before treatment assignment to rule out acute cardiopulmonary events.\n* Ascites or pericardial effusion that requires drainage, peritoneal shunt, Pleuroperitoneal shunt or CART (Concentrated Ascites Reinfusion Therapy)\n* For Part 3, Part 4 and Part 5: Active non-infectious skin disease (including any grade rash, urticarial, dermatitis, ulceration, or psoriasis) requiring systemic treatment, active or prior documented autoimmune or inflammatory disorders requiring chronic treatment with steroids or other immunosuppressive treatment.\n* Unresolved toxicities not yet resolved to Grade ≤ 1 or baseline from previous anticancer therapy OR prior discontinuation of any planned study therapy due to toxicity.\n* must not have any medical contraindication to platinum-based chemotherapy.\n* Part 3, Part 4 and Part 5 patients must not have had prior exposure to anti-PD-1, anti-PD-L1, anti-CTLA-4, anti-TIGIT or any other experimental immunotherapy in any setting.\n* For Part 3, Part 4 and Part 5: History of substance abuse or any other medical or psychological conditions that may, in the opinion of the Investigator, interfere with the subject's participation in the clinical study or evaluation of the clinical study results\n* For Part 3, Part 4 and Part 5: History of thromboembolic events within 3 months before the first dose of IP (limited to pulmonary embolism, deep vein thrombosis, or cerebral venous sinus thrombosis).",[158,159],"ADULT","OLDER_ADULT",[161,171,177,183,189,196,203,210,217,222,228,235,242,249,257,263,269,277,284,290,296,304,311,318,326,332,338,343,349,355,362,368,374,380,386,393,399,406,409,415,421,427,434,440,446,452,459,466,472,478,484,490,493,499,502,508,515,522,528,534,540,546,549,552,559,565,571,577,580,583,590,596,602,608,615,621,624,630,636,639,642,648,655,658,664,670,673,675,682,685,689],{"facility":162,"status":163,"city":164,"state":165,"zip":166,"country":167,"geoPoint":168},"Research Site","WITHDRAWN","Duarte","California","91010","United States",{"lat":169,"lon":170},34.13945,-117.97729,{"facility":162,"status":163,"city":172,"state":165,"zip":173,"country":167,"geoPoint":174},"Newport Beach","92663",{"lat":175,"lon":176},33.61891,-117.92895,{"facility":162,"status":8,"city":178,"state":165,"zip":179,"country":167,"geoPoint":180},"Orange","92868",{"lat":181,"lon":182},33.78779,-117.85311,{"facility":162,"status":163,"city":184,"state":165,"zip":185,"country":167,"geoPoint":186},"Santa Rosa","95403",{"lat":187,"lon":188},38.44047,-122.71443,{"facility":162,"status":163,"city":190,"state":191,"zip":192,"country":167,"geoPoint":193},"Westwood","Kansas","66205",{"lat":194,"lon":195},39.04056,-94.6169,{"facility":162,"status":8,"city":197,"state":198,"zip":199,"country":167,"geoPoint":200},"Baltimore","Maryland","21287",{"lat":201,"lon":202},39.29038,-76.61219,{"facility":162,"status":163,"city":204,"state":205,"zip":206,"country":167,"geoPoint":207},"Detroit","Michigan","48201",{"lat":208,"lon":209},42.33143,-83.04575,{"facility":162,"status":163,"city":211,"state":212,"zip":213,"country":167,"geoPoint":214},"Buffalo","New York","14263",{"lat":215,"lon":216},42.88645,-78.87837,{"facility":162,"status":163,"city":212,"state":212,"zip":218,"country":167,"geoPoint":219},"10029",{"lat":220,"lon":221},40.71427,-74.00597,{"facility":162,"status":163,"city":223,"state":212,"zip":224,"country":167,"geoPoint":225},"The Bronx","10461",{"lat":226,"lon":227},40.84985,-73.86641,{"facility":162,"status":8,"city":229,"state":230,"zip":231,"country":167,"geoPoint":232},"Houston","Texas","77030",{"lat":233,"lon":234},29.76328,-95.36327,{"facility":162,"status":8,"city":236,"state":237,"zip":238,"country":167,"geoPoint":239},"Fairfax","Virginia","22031",{"lat":240,"lon":241},38.84622,-77.30637,{"facility":162,"status":163,"city":243,"state":244,"zip":245,"country":167,"geoPoint":246},"Tacoma","Washington","98405",{"lat":247,"lon":248},47.25288,-122.44429,{"facility":162,"status":250,"city":251,"zip":252,"country":253,"geoPoint":254},"TERMINATED","Adelaide","5000","Australia",{"lat":255,"lon":256},-34.92866,138.59863,{"facility":162,"status":163,"city":258,"zip":259,"country":253,"geoPoint":260},"Heidelberg","3084",{"lat":261,"lon":262},-37.75,145.06667,{"facility":162,"status":8,"city":264,"zip":265,"country":253,"geoPoint":266},"Nedlands","6009",{"lat":267,"lon":268},-31.98184,115.8073,{"facility":162,"status":270,"city":271,"zip":272,"country":273,"geoPoint":274},"COMPLETED","Edegem","2650","Belgium",{"lat":275,"lon":276},51.15662,4.44504,{"facility":162,"status":8,"city":278,"zip":279,"country":280,"geoPoint":281},"Barretos","14784-400","Brazil",{"lat":282,"lon":283},-20.55722,-48.56778,{"facility":162,"status":8,"city":285,"zip":286,"country":280,"geoPoint":287},"Porto Alegre","90035-903",{"lat":288,"lon":289},-30.03283,-51.23019,{"facility":162,"status":8,"city":291,"zip":292,"country":280,"geoPoint":293},"São Paulo","05652-900",{"lat":294,"lon":295},-23.5475,-46.63611,{"facility":162,"status":163,"city":297,"state":298,"zip":299,"country":300,"geoPoint":301},"Winnipeg","Manitoba","R3E 0V9","Canada",{"lat":302,"lon":303},49.8844,-97.14704,{"facility":162,"status":163,"city":305,"state":306,"zip":307,"country":300,"geoPoint":308},"London","Ontario","N6A 5W9",{"lat":309,"lon":310},42.98339,-81.23304,{"facility":162,"status":8,"city":312,"state":313,"zip":314,"country":300,"geoPoint":315},"Montreal","Quebec","H3T 1E2",{"lat":316,"lon":317},45.50884,-73.58781,{"facility":162,"status":319,"city":320,"zip":321,"country":322,"geoPoint":323},"NOT_YET_RECRUITING","Changchun","130000","China",{"lat":324,"lon":325},43.88,125.32278,{"facility":162,"status":319,"city":327,"zip":328,"country":322,"geoPoint":329},"Chengdu","610041",{"lat":330,"lon":331},30.66667,104.06667,{"facility":162,"status":319,"city":333,"zip":334,"country":322,"geoPoint":335},"Fuzhou","350011",{"lat":336,"lon":337},26.06139,119.30611,{"facility":162,"status":319,"city":339,"country":322,"geoPoint":340},"Shandong",{"lat":341,"lon":342},40.28464,120.48412,{"facility":162,"status":8,"city":344,"zip":345,"country":322,"geoPoint":346},"Shanghai","200433",{"lat":347,"lon":348},31.22222,121.45806,{"facility":162,"status":319,"city":350,"zip":351,"country":322,"geoPoint":352},"Zhengzhou","450000",{"lat":353,"lon":354},34.75778,113.64861,{"facility":162,"status":163,"city":356,"zip":357,"country":358,"geoPoint":359},"Bordeaux","33075","France",{"lat":360,"lon":361},44.84124,-0.58046,{"facility":162,"status":8,"city":363,"zip":364,"country":358,"geoPoint":365},"Dijon","21079",{"lat":366,"lon":367},47.31344,5.01391,{"facility":162,"status":8,"city":369,"zip":370,"country":358,"geoPoint":371},"Pierre-Bénite","69495",{"lat":372,"lon":373},45.70359,4.82424,{"facility":162,"status":8,"city":375,"zip":376,"country":358,"geoPoint":377},"Saint-Herblain","44800",{"lat":378,"lon":379},47.21154,-1.651,{"facility":162,"status":8,"city":381,"zip":382,"country":358,"geoPoint":383},"Villejuif","94805",{"lat":384,"lon":385},48.7939,2.35992,{"facility":162,"status":8,"city":387,"zip":388,"country":389,"geoPoint":390},"Kfar Saba","4428164","Israel",{"lat":391,"lon":392},32.175,34.90694,{"facility":162,"status":8,"city":394,"zip":395,"country":389,"geoPoint":396},"Qiryat Krinitzi","52620",{"lat":397,"lon":398},32.0546,34.84588,{"facility":162,"status":270,"city":400,"zip":401,"country":402,"geoPoint":403},"Milan","20133","Italy",{"lat":404,"lon":405},42.78235,12.59836,{"facility":162,"status":8,"city":400,"zip":407,"country":402,"geoPoint":408},"20162",{"lat":404,"lon":405},{"facility":162,"status":8,"city":410,"zip":411,"country":402,"geoPoint":412},"Monza","20052",{"lat":413,"lon":414},45.58005,9.27246,{"facility":162,"status":8,"city":416,"zip":417,"country":402,"geoPoint":418},"Naples","80131",{"lat":419,"lon":420},40.85216,14.26811,{"facility":162,"status":163,"city":422,"zip":423,"country":402,"geoPoint":424},"Padova","35128",{"lat":425,"lon":426},44.38225,11.14261,{"facility":162,"status":8,"city":428,"zip":429,"country":430,"geoPoint":431},"George Town","10450","Malaysia",{"lat":432,"lon":433},5.41123,100.33543,{"facility":162,"status":8,"city":435,"zip":436,"country":430,"geoPoint":437},"Kuala Lumpur","59100",{"lat":438,"lon":439},3.1412,101.68653,{"facility":162,"status":8,"city":441,"zip":442,"country":430,"geoPoint":443},"Kuala Selangor","62250",{"lat":444,"lon":445},3.35,101.25,{"facility":162,"status":8,"city":447,"zip":448,"country":430,"geoPoint":449},"Kuching","93586",{"lat":450,"lon":451},1.55,110.33333,{"facility":162,"status":270,"city":453,"zip":454,"country":455,"geoPoint":456},"Amsterdam","1066 CX","Netherlands",{"lat":457,"lon":458},52.37403,4.88969,{"facility":162,"status":8,"city":460,"zip":461,"country":462,"geoPoint":463},"Bacolod","6100","Philippines",{"lat":464,"lon":465},8.11667,123.91667,{"facility":162,"status":163,"city":467,"zip":468,"country":462,"geoPoint":469},"Cebu City","6000",{"lat":470,"lon":471},10.31672,123.89071,{"facility":162,"status":163,"city":473,"zip":474,"country":462,"geoPoint":475},"City of Taguig","1634",{"lat":476,"lon":477},14.5243,121.0792,{"facility":162,"status":250,"city":479,"zip":480,"country":462,"geoPoint":481},"Davao City","PH-8000",{"lat":482,"lon":483},7.07306,125.61278,{"facility":162,"status":250,"city":485,"zip":486,"country":462,"geoPoint":487},"Manila","1000",{"lat":488,"lon":489},14.6042,120.9822,{"facility":162,"status":163,"city":485,"zip":491,"country":462,"geoPoint":492},"1015",{"lat":488,"lon":489},{"facility":162,"status":8,"city":494,"zip":495,"country":462,"geoPoint":496},"Quezon City","1100",{"lat":497,"lon":498},14.6488,121.0509,{"facility":162,"status":8,"city":494,"zip":500,"country":462,"geoPoint":501},"1112",{"lat":497,"lon":498},{"facility":162,"status":250,"city":503,"zip":504,"country":462,"geoPoint":505},"San Juan City","1500",{"lat":506,"lon":507},14.6,121.0333,{"facility":162,"status":8,"city":509,"zip":510,"country":511,"geoPoint":512},"Gdansk","80-214","Poland",{"lat":513,"lon":514},54.35227,18.64912,{"facility":162,"status":516,"city":517,"zip":518,"country":511,"geoPoint":519},"SUSPENDED","Krakow","30-727",{"lat":520,"lon":521},50.06143,19.93658,{"facility":162,"status":8,"city":523,"zip":524,"country":511,"geoPoint":525},"Olsztyn","10-357",{"lat":526,"lon":527},53.78376,20.49272,{"facility":162,"status":250,"city":529,"zip":530,"country":511,"geoPoint":531},"Tomaszów Mazowiecki","97-200",{"lat":532,"lon":533},51.53131,20.00855,{"facility":162,"status":8,"city":535,"zip":536,"country":511,"geoPoint":537},"Warsaw","02-781",{"lat":538,"lon":539},52.22977,21.01178,{"facility":162,"status":270,"city":541,"zip":542,"country":541,"geoPoint":543},"Singapore","119228",{"lat":544,"lon":545},1.28967,103.85007,{"facility":162,"status":270,"city":541,"zip":547,"country":541,"geoPoint":548},"168583",{"lat":544,"lon":545},{"facility":162,"status":270,"city":541,"zip":550,"country":541,"geoPoint":551},"308433",{"lat":544,"lon":545},{"facility":162,"status":8,"city":553,"zip":554,"country":555,"geoPoint":556},"Cheongju-si","28644","South Korea",{"lat":557,"lon":558},36.63722,127.48972,{"facility":162,"status":8,"city":560,"zip":561,"country":555,"geoPoint":562},"Goyang-si","10408",{"lat":563,"lon":564},37.65639,126.835,{"facility":162,"status":8,"city":566,"zip":567,"country":555,"geoPoint":568},"Jinju","52727",{"lat":569,"lon":570},35.19278,128.08472,{"facility":162,"status":8,"city":572,"zip":573,"country":555,"geoPoint":574},"Seoul","03722",{"lat":575,"lon":576},37.566,126.9784,{"facility":162,"status":163,"city":572,"zip":578,"country":555,"geoPoint":579},"05505",{"lat":575,"lon":576},{"facility":162,"status":8,"city":572,"zip":581,"country":555,"geoPoint":582},"06351",{"lat":575,"lon":576},{"facility":162,"status":163,"city":584,"zip":585,"country":586,"geoPoint":587},"Badalona","08013","Spain",{"lat":588,"lon":589},41.45004,2.24741,{"facility":162,"status":163,"city":591,"zip":592,"country":586,"geoPoint":593},"Madrid","28041",{"lat":594,"lon":595},40.4165,-3.70256,{"facility":162,"status":163,"city":597,"zip":598,"country":586,"geoPoint":599},"Seville","41013",{"lat":600,"lon":601},37.38283,-5.97317,{"facility":162,"status":163,"city":603,"zip":604,"country":586,"geoPoint":605},"Valencia","46010",{"lat":606,"lon":607},39.47391,-0.37966,{"facility":162,"status":8,"city":609,"zip":610,"country":611,"geoPoint":612},"Kaohsiung City","833","Taiwan",{"lat":613,"lon":614},22.61626,120.31333,{"facility":162,"status":8,"city":616,"zip":617,"country":611,"geoPoint":618},"Taichung","402",{"lat":619,"lon":620},24.1469,120.6839,{"facility":162,"status":8,"city":616,"zip":622,"country":611,"geoPoint":623},"40705",{"lat":619,"lon":620},{"facility":162,"status":8,"city":625,"zip":626,"country":611,"geoPoint":627},"Tainan","70403",{"lat":628,"lon":629},22.99083,120.21333,{"facility":162,"status":8,"city":631,"zip":632,"country":611,"geoPoint":633},"Taipei","100",{"lat":634,"lon":635},25.05306,121.52639,{"facility":162,"status":8,"city":631,"zip":637,"country":611,"geoPoint":638},"11217",{"lat":634,"lon":635},{"facility":162,"status":8,"city":631,"zip":640,"country":611,"geoPoint":641},"235",{"lat":634,"lon":635},{"facility":162,"status":8,"city":643,"zip":644,"country":611,"geoPoint":645},"Taoyuan","333",{"lat":646,"lon":647},24.99368,121.29696,{"facility":162,"status":8,"city":649,"zip":650,"country":651,"geoPoint":652},"Bangkok","10300","Thailand",{"lat":653,"lon":654},13.75398,100.50144,{"facility":162,"status":270,"city":649,"zip":656,"country":651,"geoPoint":657},"10330",{"lat":653,"lon":654},{"facility":162,"status":270,"city":659,"zip":660,"country":651,"geoPoint":661},"Hat Yai","90110",{"lat":662,"lon":663},7.00836,100.47668,{"facility":162,"status":270,"city":665,"zip":666,"country":651,"geoPoint":667},"Khon Kaen","40002",{"lat":668,"lon":669},16.44671,102.833,{"facility":162,"status":319,"city":671,"zip":672,"country":651},"Muang","22000",{"facility":162,"status":8,"city":671,"zip":674,"country":651},"50200",{"facility":162,"status":8,"city":676,"zip":677,"country":678,"geoPoint":679},"Ankara","06800","Turkey (Türkiye)",{"lat":680,"lon":681},39.91987,32.85427,{"facility":162,"status":8,"city":676,"zip":683,"country":678,"geoPoint":684},"6200",{"lat":680,"lon":681},{"facility":162,"status":686,"city":687,"zip":688,"country":678},"ACTIVE_NOT_RECRUITING","Bornova-Izmir","35100",{"facility":162,"status":8,"city":690,"zip":691,"country":678,"geoPoint":692},"Istanbul","31755",{"lat":693,"lon":694},41.01384,28.94966,[696,701],{"name":697,"role":698,"phone":699,"email":700},"AstraZeneca Clinical Study Information Center","CONTACT","1-877-240-9479","information.center@astrazeneca.com",{"name":702,"role":698,"phone":703,"email":704},"AstraZeneca Lung Cancer Study Locator Service","1-884-432-3892","az-lcsl@careboxhealth.com",[],[707],{"pmid":708,"type":709,"citation":710},"41448488","DERIVED","Planchard D, Kim HR, Suksombooncharoen T, Li R, Cortinovis D, Han JY, Samol J, Runglodvatana Y, Lee KY, Chang GC, Lee CH, Kowalski D, Saw SPL, Huang Y, Ruiter G, Ahn MJ, Yang TY, Yang CT, Sookprasert A, Nakajima EC, Alfon J, McEwen R, Chang YT, Yang JC. Trastuzumab Deruxtecan in Patients With HER2-Overexpressing NSCLC: Results From Part 1 of the Open-Label, Multicenter, Phase 1b DESTINY-Lung03 Trial. J Thorac Oncol. 2026 May;21(5):103541. doi: 10.1016\u002Fj.jtho.2025.12.080. Epub 2025 Dec 23.",[712],{"label":713,"url":714},"Lung Cancer Study Locator details (for US)","https:\u002F\u002Fwww.lungcancerstudylocator.com\u002Ftrial\u002Flisting\u002F264517",{"nct_id":4,"conditions":716,"biomarkers":718},[717],"Lung Non-Small Cell Carcinoma",[],{"nct_id":4,"found":720,"summary":721,"prompt_version":128},true,{"design":722,"status":723,"heading":724,"summary":725,"follow_up":726,"word_count":727,"commitments":728,"compensation":729,"drugs_mentioned":730},"This is an interventional study, meaning participants will receive specific treatments. It involves different parts, including dose escalation and expansion, to find the safest and most effective drug combinations.","completed","Study of T-DXd and Immunotherapy for HER2+ Lung Cancer","This study is looking at the safety of combining trastuzumab deruxtecan (T-DXd) with immunotherapy drugs (like durvalumab, volrustomig, or rilvegostomig), sometimes with chemotherapy (cisplatin or carboplatin), for people with advanced non-small cell lung cancer that has too much of a protein called HER2. The study wants to find the best and safest dose of these combinations. You might be able to join if your cancer has progressed after other treatments or if you have certain types of cancer without specific genetic changes. The study will also look at how well these treatments work. The current status of this study is unclear, and it plans to enroll 304 people.","Safety and tolerability will be assessed for approximately 20 months from when you give your informed consent.",108,"Not specified in the trial record.","Not stated in the trial record.",[24,62,68,31]]